Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicine set out in the Schedule hereto:
|Active Ingredient:||Daunorubicin hydrochloride 2.14mg/mL equivalent to daunorubicin 2mg/mL|
|Dosage Form:||Solution for injection|
|New Zealand Sponsor:||Pfizer New Zealand Limited|
|Manufacturer:||Bridgewest Perth Pharma Pty Limited, Perth, Australia|
Note: This renewed consent is valid for two years from 26 September 2023.
Dated this 22nd day of September 2023.
DEREK FITZGERALD, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).